Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with ...

Glucagon-like peptide 1 receptor agonist treatment is not associated with an increased risk for psychiatric adverse events or worsening depressive symptoms.

There were associations for GLP-1 RA treatment vs placebo with improvements in restrained eating and emotional eating behavior and in mental health-related QOL. HealthDay News — For patients ...

Patients with diabetes mellitus who use GLP-1 RAs have an increased risk for acute and chronic pancreatitis, according to a study presented at DDW 2025.

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

But the pause brought renewed attention to one of the biggest challenges in health care today, one that played a role in GIC’s woes: the high price of popular GLP-1 drugs to treat obesity.

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still prefer to lose weight without using medications. For those preferring a drug ...

Risks for prostate cancer metastasis or death appeared lower with GLP-1 RA use compared with use of other antidiabetic drugs. Patients with prostate cancer who take glucagon-like peptide-1 ...

Hims had sold one-month doses of compounded GLP-1 semaglutides starting at $165 per month. The list cost of Wegovy is $1,349, and one dose is generally taken every four weeks. More recently ...